DB Summary Table 9 [Bioanalytics]

posted by AngusMcLean – USA, 2013-05-15 02:38 (4398 d 04:20 ago) – Posting: # 10584
Views: 4,677

Pharmacokinetic outlier

I think it is important to have an SOP in place and issued prior to running the study. It should be defined what the criteria are for identifying a "pharmacokinetic outlier" and repeat of the assay. The repeat data should be examined in accord with the lab. SOP for accepting and rejecting repeat assays.


The FDA will review above.

Angus

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,678 registered users;
122 visitors (0 registered, 122 guests [including 11 identified bots]).
Forum time: 06:59 CEST (Europe/Vienna)

If you want to get people to believe
something really, really stupid,
just stick a number on it.    Charles Seife

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5